Navigation Links
Lilly Reports First-Quarter 2011 Results
Date:4/18/2011

he first quarter of 2011. Earnings per share guidance excludes potential future restructuring charges.

2011 Earnings Per Share Expectations:2011

Expectations2010

Results% GrowthEarnings per share (reported)$3.86 to $4.01$4.58(12)% to (16)%In-process research and development charge

  associated with Boehringer Ingelheim

  collaboration (2011) and Acrux licensing

  agreement (2010).23.03Asset impairments and restructuring charges

.06.13Earnings per share (non-GAAP)$4.15 to $4.30$4.74(9)% to (12)%Due to the recent appreciation of several foreign currencies versus the U.S. dollar, the company now expects total revenue to grow in the low-single digits, an increase from the prior guidance of flat to slightly increasing total revenue growth. The company still anticipates that the impact of U.S. health care reform will lower 2011 revenue by $400 million to $500 million. 2011 revenue guidance assumes the company maintains its patent exclusivity for U.S. Strattera sales, and also assumes rapid and severe erosion of global Zyprexa sales after patent expirations in major markets, including the U.S. starting in October 2011, and the continued severe erosion of U.S. Gemzar sales. The company expects these reductions in revenue to be offset by sales growth of Alimta, Cialis, Cymbalta, Effient, Humalog and animal health products.

Due to the recent appreciation of several foreign currencies versus the U.S. dollar, the company now anticipates that gross margin as a percent of revenue will decline approximately 3 percentage points, a revision from prior guidance of an approximate 2 percentage point decline.

Marketing, selling and administrative expenses are still projected to grow in the low- to mid-single digits and include an estimated $150 million to $200 million in non-tax deductible expense for the mandatory pharmaceutical manufacturers fee associated with U.S. health care reform. Research and deve
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014  United Therapeutics Corporation (NASDAQ: UTHR ... the District of New Jersey ... against Sandoz, Inc. regarding United Therapeutics, Remodulin ® ... that U.S. Patent No. 6,765,117 is both valid and ... its generic product until the expiration of that patent ...
(Date:8/29/2014)... Aug. 29, 2014 /PRNewswire-iReach/ -- ChemImage will present a ... and New Zealand Forensic Science Society,s 22 nd ... Adelaide, Australia .  Forensic Scientists ... advancements that hyperspectral imaging can bring to examination ... , Director of Product Development at ChemImage, will ...
(Date:8/29/2014)... MENLO PARK, Calif. , Aug. 29, ... (OTCQB: DMPI) ("DelMar" "the Company") today announced the filing ... Company recently changed its fiscal year end to June ... its common stock on a national securities exchange in ... as filed with the United States Securities Exchange Commission ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5
(Date:8/29/2014)... (PRWEB) August 29, 2014 A team ... wellness solutions, is on its way to the 2014 ... San Diego Convention Center to exhibit and demonstrate a ... in high-noise industrial environments. Etymotic’s safety earphones and high-definition ... technology devices at the show. , The company’s ...
(Date:8/29/2014)... City, Calif. (PRWEB) August 29, 2014 ... and customer service solutions, today announced that LiveOps has ... Muscular Dystrophy Association's (MDA) Show of Strength Telethon for ... entertainment event raises money and awareness to support MDA’s ... dystrophy, an aggressive and sometimes fatal muscle disease. This ...
(Date:8/29/2014)... 29, 2014 (HealthDay News) -- Prostate cancer patients lacking ... decisions. This can lead to worse quality of care ... included 70 men, with a median age of 63. ... Poor understanding of the disease was associated with greater ... that the treatment would be effective, the study found. ...
(Date:8/29/2014)... Medicine have identified one way the Ebola virus dodges ... lead to new therapies, in research results ... . , In work performed at Beamline 19ID at ... a detailed map of how a non-pathogenic Ebola protein, ... molecules in and out of the cell nucleus. , ...
(Date:8/29/2014)... Pittsburgh, PA (PRWEB) August 29, 2014 ... inventor from Harrisburg, Pa., had to have breast reconstruction. ... to be sub-par, so she decided that there needed ... a better look for a woman or man who ... visible, as well as promotes confidence and peace of ...
Breaking Medicine News(10 mins):Health News:Etymotic’s Safe Listening Earphones and Earplugs Headed For The 2014 NSC Safety Expo 2Health News:LiveOps Supports Muscular Dystrophy Association Show of Strength Telethon 2Health News:LiveOps Supports Muscular Dystrophy Association Show of Strength Telethon 3Health News:LiveOps Supports Muscular Dystrophy Association Show of Strength Telethon 4Health News:Faced With Prostate Cancer, It Helps to Know the Enemy 2
... function a serious concern, researchers say , TUESDAY, Jan. 26 (HealthDay ... with the virus that causes AIDS, new research suggests. , It,s ... -- or both -- are contributing to the aging. But one ... the same as in those of uninfected people who are 15 ...
... Clinicians use Epocrates ... ... -- Epocrates, Inc., a leading developer of mobile clinical and decision support software, ... 2009. The market demand and clinician need for its mobile and online solutions among large ...
... progression, study finds , TUESDAY, Jan. 26 (HealthDay ... drug pazopanib (Votrient) slowed their disease progression by 54 ... 3 study included 233 patients with previously untreated kidney ... locally advanced or had spread, and 202 patients with ...
... ... to push fans to reach their fitness goals with the 5-Hour Energy Workout Challenge. , ... Farmington Hills, MI (PRWEB) January 26, 2010 -- ... fitness goals with the 5-Hour Energy Workout Challenge ., , , , ,The Workout Challenge ...
... , SYRACUSE, N.Y. , Jan. 26 ... recent earthquake in Haiti , Aspen Dental Management, Inc. (ADMI) ... ," a voluntary program that gives Aspen Dental employees the option ... Red Cross for Haiti relief and development. Aspen Dental ...
... As the debates about "eat this -- not that" ... the record straight about what sweetens most of the non-diet beverages ... Syrup 55 (HFCS), not sugar (sucrose).   , In hundreds of ... sugar is misidentified as a prominent soda sweetener. Terms like "sugary ...
Cached Medicine News:Health News:Premature Aging of the Brain Seen in HIV Patients 2Health News:Health Systems, Hospitals and Universities Nationwide Chose Epocrates in 2009 for Trusted Point-of-Care Clinical Information 2Health News:Health Systems, Hospitals and Universities Nationwide Chose Epocrates in 2009 for Trusted Point-of-Care Clinical Information 3Health News:New Drug Slows Advanced Kidney Cancer 2Health News:The 5-Hour Energy Workout Challenge 2Health News:The 5-Hour Energy Workout Challenge 3Health News:Aspen Dental Employees to Give 'An Hour for Haiti' 2Health News:Sugar Association Seeks to Set the Record Straight on 'Sugar-Sweetened Beverage' Terminology 2
IDS Rapid One, a microbial identification system....
IDS Rapid NF Plus, a microbial identification system....
Versatrek 240 is versatile as four tests can be performed on one platform such as blood culture, sterile body fluids, mycobacteria and mycobacteria susceptibility testing. This model comes equipped w...
BD Phoenix is an automated microbiology system used for identification and susceptibility testing....
Medicine Products: